University Of Szeged

At the University of Szeged Gastroenterology Clinic, investigators study disorders of the gastrointestinal tract, testing new therapies and diagnostic tools to improve patient outcomes.

• Evaluation of biologic agents for moderate to severe Crohn's disease
• Assessing novel oral formulations for ulcerative colitis
• Investigating endoscopic techniques for gastroesophageal reflux disease
• Studying microbiome‑targeted interventions in irritable bowel syndrome
• Safety profiling of peptide therapies for intestinal inflammation

With more than 300 active studies and a team of 20 investigators, the site contributes significantly to advancing gastrointestinal care in Central Europe.

The cardiovascular research program at University of Szeged addresses heart failure, atherosclerosis and arrhythmias, aiming to test innovative drugs and preventive strategies.

• Phase trials of RNA‑based inhibitors to lower lipoprotein(a)
• Comparative studies of anticoagulants in patients with atrial fibrillation
• Evaluation of novel SGLT2 inhibitors for heart failure with preserved ejection fraction
• Prevention trials targeting major adverse cardiovascular events in high‑risk populations
• Safety assessment of combined therapy for chronic coronary syndrome

The department collaborates with cardiology units across Hungary, supporting robust recruitment for multicenter cardiovascular investigations.

Oncologic trials at the Szeged site span solid tumors and hematologic malignancies, focusing on targeted agents, immunotherapies and combination regimens.

• Testing checkpoint inhibitors in advanced melanoma with brain metastases
• Adjuvant therapy evaluation for hepatocellular carcinoma after resection
• Phase studies of kinase inhibitors in non‑clear cell renal cell carcinoma
• Assessing antibody‑drug conjugates for triple‑negative breast cancer
• Investigating CAR‑T cell approaches for relapsed B‑cell acute lymphoblastic leukemia

The oncology unit leverages a network of surgical and radiotherapy partners, enhancing comprehensive cancer care research.

Researchers explore autoimmune and inflammatory disorders, evaluating biologics and small molecules to modulate immune pathways.

• Efficacy of IL‑23 inhibitors in psoriatic arthritis
• Safety of JAK inhibitors for systemic lupus erythematosus
• Clinical response of anti‑IgE therapy in chronic spontaneous urticaria
• Targeting B‑cell activation in primary membranous nephropathy
• Novel oral agents for rheumatoid arthritis

The multidisciplinary team includes rheumatology, nephrology and dermatology specialists, fostering integrated autoimmune research.

The dermatology research agenda investigates severe skin conditions, aiming to provide effective, patient‑centered treatments.

• Comparative trial of bimekizumab versus risankizumab for moderate to severe psoriasis
• Phase study of rocatinlimab to reduce pruritus in prurigo nodularis
• Assessing dupilumab versus upadacitinib in pediatric atopic dermatitis
• Investigating oral agents for alopecia areata
• Safety monitoring of systemic therapies for bullous pemphigoid

With dedicated dermatology clinics, the site enrolls patients rapidly, supporting swift advancement of skin disease therapeutics.

Neurological studies at Szeged target neurodegenerative and neuroinflammatory disorders, seeking disease‑modifying options.

• Evaluating monoclonal antibodies for Alzheimer's disease‑related agitation
• Trial of oral agents for Tourette's disorder
• Assessing neuroprotective compounds in acute ischemic stroke
• Safety of immunotherapy in glioblastoma multiforme
• Investigating disease progression markers in multiple sclerosis

Collaboration with the university's neurology department enables access to specialized imaging and biomarker facilities.

Metabolic research focuses on obesity, diabetes and lipid disorders, testing interventions that reduce cardiovascular risk and improve metabolic health.

• Long‑term study of retatrutide for weight management in patients with established CVD
• Inclisiran trials to lower LDL‑cholesterol and prevent events
• Investigating GLP‑1 receptor agonists for type 2 diabetes with obesity
• Evaluating lifestyle‑integrated programs for non‑alcoholic fatty liver disease
• Safety analysis of novel agents for hypertriglyceridemia

The metabolic unit partners with endocrinology and nutrition services to ensure comprehensive trial support.

Infectious disease trials address bacterial, viral and fungal pathogens, aiming to improve treatment efficacy and reduce resistance.

• Phase studies of new antibiotics for Clostridioides difficile infection
• Evaluating antiviral regimens for SARS‑CoV‑2 in hospitalized patients
• Assessing immunomodulators in sepsis‑associated acute kidney injury
• Safety of combination therapy for hepatitis B chronic infection
• Preventive trial of vaccines against respiratory syncytial virus

The site’s microbiology lab supports rapid diagnostics, facilitating timely enrollment in acute infection studies.